Market-Moving News for June 6th
$FRGT
$NVAX
$ONMD
Professional Services
Consumer Discretionary
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 10/24/2025 | $18.00 | Overweight | Cantor Fitzgerald | |
| 8/28/2025 | $10.00 | Buy | H.C. Wainwright | |
| 8/20/2025 | $7.00 | Neutral → Underperform | BofA Securities | |
| 6/17/2025 | $6.00 | Sell | Citigroup | |
| 2/28/2025 | $19.00 | Buy | BTIG Research | |
| 7/30/2024 | $8.00 | Neutral → Underweight | JP Morgan | |
| 5/10/2024 | $4.00 → $12.00 | Underperform → Neutral | BofA Securities | |
| 5/10/2024 | Underweight → Neutral | JP Morgan |
4 - OneMedNet Corp (0001849380) (Issuer)
4 - OneMedNet Corp (0001849380) (Issuer)
4 - OneMedNet Corp (0001849380) (Issuer)
SCHEDULE 13G - NOVAVAX INC (0001000694) (Subject)
8-K - NOVAVAX INC (0001000694) (Filer)
8-K - NOVAVAX INC (0001000694) (Filer)
For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons
For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of
For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO
Cantor Fitzgerald resumed coverage of Novavax with a rating of Overweight and set a new price target of $18.00
H.C. Wainwright resumed coverage of Novavax with a rating of Buy and set a new price target of $10.00
BofA Securities downgraded Novavax from Neutral to Underperform and set a new price target of $7.00
4 - NOVAVAX INC (0001000694) (Issuer)
4 - OneMedNet Corp (0001849380) (Issuer)
4 - NOVAVAX INC (0001000694) (Issuer)
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – The global medical imaging market hit a massive $45.5 billion in 2026[1], marking a total structural shift toward AI-native precision as advanced cancer therapies demand more intense heart monitoring than ever before[2]. Hospitals are ditching expensive, bulky hardware for agile, cloud-based platforms that deliver MRI-quality results without the MRI-sized price tag. This pivot has catapulted the cardiac AI diagnostic sector to $2.22 billion this year[3], driven by a desperate need for continuous imaging to catch heart dysfunction caused by cancer treatments[4]. Thi
HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Freight Technologies, Inc. (NASDAQ:FRGT, "Fr8Tech" or the "Company")), a logistics technology company, today announced the strategic launch of Zayren Pro, a premium commercial evolution of its AI-driven predictive pricing and matching platform. The release builds on the successful debut of Zayren in November 2025 and will contribute to the Company's subscription-based SaaS revenue. Developed by Fr8Tech's in-house AI Lab, Zayren Pro transitions the Company's AI strategy from market visibility to actionable procurement execution. This new tier introduces advanced agentic AI capabilities, provides for unlimited query capacity, and establishes a prop
MINNEAPOLIS, Jan. 22, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD), a leading provider of regulatory-grade, AI-ready Real-World Data (RWD), today announced that its high-quality, multimodal clinical data supported mlHealth 360 in obtaining U.S. Food and Drug Administration (FDA) 510(k) clearance for Scaida BrainCT-ICH, an AI-powered software solution designed to facilitate the rapid detection of intracranial hemorrhage (ICH) from head computed tomography (CT) scans. Scaida BrainCT-ICH leverages artificial intelligence to analyze head CT images and identify suspected intracranial hemorrhage in approximately 5.97 seconds after image acquisition, enabling faster clinical tria
Celebration, FL, Dec. 30, 2025 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ: LRHC) ("La Rosa" or the "Company"), a real estate and PropTech company, today announced that the Company's Board of Directors (the "Board") has appointed Mr. Nicholas Adler as a member of the Board, effective December 29, 2025. Upon his appointment, Mr. Adler was also named Chairman of the Board, Chairman of the Compensation Committee, and a member of both the Audit Committee and the Nominating and Corporate Governance Committee. Additionally, on December 29, 2025, Mr. Siamack Alavi notified the Board of his resignation as a director of the Company, effective immediately. Mr. Alavi also stepped down from hi
HOUSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Freight Technologies, Inc. (NASDAQ:FRGT, "Fr8Tech" or the "Company")), a logistics management innovation company offering a diverse portfolio of technology-driven solutions, today announced the commercial launch of Zayren, an artificial intelligence ("AI") based, machine learning pricing-prediction tool and carrier-matching platform designed specifically for cross-border and domestic over-the-road ("OTR") freight shipments across Mexico and the United States. Developed by Fr8Tech's in-house AI Lab or the Artificial Intelligence Lab, Zayren provides real-time freight-rate predictions, enabling shippers and brokers to access instant pricing insight
GAITHERSBURG, Md., April 29, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced the appointment of Charles Newton to its board as an independent director. Mr. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. "Charles brings a wealth of expertise across corporate finance and capital markets to Novavax," said John C. Jacobs, President and Chief Executive Officer, Novavax. "The knowledge he brings to our already experienced board will be invaluable as we continue to execute our corp
MINNEAPOLIS, Nov. 17, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) ("OneMedNet," the "Company," "we," "us" or "our"), a leader in AI-powered Real-World Data (RWD), announced its financial results for the third quarter ended September 30, 2025 and operational highlights. Third Quarter Financial Highlights Bookings: $1.1M in third quarter 2025 bookings, an 815% increase compared to third quarter of 2024.Private Placements: Successfully completed an additional $0.5M private placement of common stock from an insider, providing further investment towards strategic objectives.Further Improved Balance Sheet: Continuing with its efforts first reported at the end of the second qu
Total revenue of $70 million in the third quarter of 2025Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date including $50 million earned on marketing authorization transfersSanofi reported preliminary positive immunogenicity and safety Phase 1/2 data for Nuvaxovid™ in combination with both Fluzone High-Dose and FlublokSanofi received BARDA grant for pandemic influenza vaccine candidate using Novavax's Matrix-M® adjuvantMaryland site consolidation transactions resulted in $60 million cash proceeds and approximately $230 million in expected future cost savingsRaises Full Year 2025 Revenue Framework and Affirms Financial GuidanceCompany to
GAITHERSBURG, Md., Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, November 6, 2025. Details of the event and replay are as follows: Conference call details: Date: November 6, 2025 Time: 8:30 a.m. ET URL to register phone: Register Here Dial-in number: (888) 880-3330 (U.S.) or (+1) (646) 357-8766 (International) Webcast: ir.novavax.com/events Participants can join the conference call without operator assistance by registering and entering thei
SC 13G/A - NOVAVAX INC (0001000694) (Subject)
SC 13G - OneMedNet Corp (0001849380) (Subject)
SC 13G/A - NOVAVAX INC (0001000694) (Subject)